Dossier assessment
Blinatumomab (first relapsed ALL, children < 1 year) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Report documents
-
Dossier assessment
Blinatumomab (first relapsed ALL, children < 1 year) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Project details
- Project no.
- G25-08
- Commission
- Commission awarded on 27.02.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Health Economics
- Topic
- Cancer
- Note
-
In accordance with §35a (1) Sentence 11 Social Code Book (SGB) V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. On behalf of the Federal Joint Committee (GBA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.
After completion of the assessment by IQWiG, the GBA conducts a commenting procedure. Following the hearing, the GBA decides on the extent of the added benefit. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA Website.
- DOI
https://doi.org/10.60584/G25-08
Connected Projects
-
Dossier assessment
Blinatumomab (acute lymphoblastic leukaemia, Ph-, CD19+, children aged 1 to 18 years) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Blinatumomab (acute lymphoblastic leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Blinatumomab (ALL, paediatric patients) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Blinatumomab (ALL, MRD-positive patients) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Blinatumomab (acute lymphoblastic leukaemia)- Assessment according to §35a (para. 1., sentence 10) Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Blinatumomab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V
Status: Commission completed
-
Dossier assessment
Blinatumomab (refractory ALL, children < 1 year) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Blinatumomab (ALL, adults) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Blinatumomab (B-ALL, high-risk first relapsed, children and adolescents >= 1 month) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Blinatumomab (B-ALL, 1st and 2nd complete remission) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Blinatumomab (B-ALL, newly diagnosed, consolidation therapy) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Blinatumomab (B-ALL, refractory or relapsed, children and adolescents >= 1 month) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Blinatumomab (B-ALL, relapsed or refractory) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed